Fmr LLC Hille Vax, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Hille Vax, Inc. stock. As of the latest transaction made, Fmr LLC holds 554 shares of HLVX stock, worth $1,013. This represents 0.0% of its overall portfolio holdings.

Number of Shares

554

Previous 496 11.69%

Holding current value

$1,013

Previous $8,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$11.86 - $15.93 $687 - $923	58 Added 11.69%	554 $8,000
Q1 2024 May 13, 2024	BUY	$14.15 - $19.75 $3,367 - $4,700	238 Added 92.25%	496 $8,000
Q4 2023 Feb 13, 2024	SELL	$10.35 - $17.11 $8,290 - $13,705	-801 Reduced 75.64%	258 $4,000
Q3 2023 Nov 13, 2023	BUY	$11.59 - $16.7 $8,391 - $12,090	724 Added 216.12%	1,059 $14,000
Q2 2023 Aug 11, 2023	SELL	$12.93 - $18.76 $2,223 - $3,226	-172 Reduced 33.93%	335 $5,000
Q1 2023 May 11, 2023	BUY	$14.73 - $18.18 $4,964 - $6,126	337 Added 198.24%	507 $8,000
Q4 2022 Feb 13, 2023	SELL	$13.52 - $21.46 $986 - $1,566	-73 Reduced 30.04%	170 $2,000
Q3 2022 Nov 10, 2022	BUY	$10.5 - $22.01 $2,394 - $5,018	228 Added 1520.0%	243 $4,000
Q2 2022 Aug 12, 2022	BUY	$8.7 - $20.18 $130 - $302	15 New	15 $0

Others Institutions Holding HLVX

# of Institutions

Shares Held

40.5M

Call Options Held

Put Options Held

Frazier Life Sciences Management, L.P. Menlo Park, CA

10.6M
Shares

$19.4 Million
9.05% of portfolio
Deerfield Management Company, L.P. (Series C) New York, NY

4M
Shares

$7.33 Million
1.22% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

3.48M
Shares

$6.37 Million
0.03% of portfolio
Black Rock Inc. New York, NY

2.09M
Shares

$3.83 Million
0.0% of portfolio
Franklin Resources Inc San Mateo, CA

1.99M
Shares

$3.64 Million
0.01% of portfolio

View Full List

About HilleVax, Inc.

Ticker HLVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,427,200
Market Cap $61.2M
Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

More about HLVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account